{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T14:41:18Z","timestamp":1786545678167,"version":"build-2736575974"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,11]]},"DOI":"10.1111\/j.1572-0241.2008.02086.x","type":"journal-article","created":{"date-parts":[[2008,8,21]],"date-time":"2008-08-21T12:04:13Z","timestamp":1219320253000},"page":"2776-2783","source":"Crossref","is-referenced-by-count":107,"title":["Efficacy and Safety of Entecavir in Patients With Chronic Hepatitis B and Advanced Hepatic Fibrosis or Cirrhosis"],"prefix":"10.14309","volume":"103","author":[{"given":"Eugene","family":"Schiff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halis","family":"Simsek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William M.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You-Chen","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoel","family":"Sette, Jr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry L.A.","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven-Huy","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Brett-Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Tamez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"10.1111\/j.1572-0241.2008.02086.x-BIB1","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(06)69347-1","article-title":"Prevention of mortality from hepatitis B and hepatitis C","volume":"368","author":"Schiff","year":"2006","journal-title":"Lancet"},{"key":"10.1111\/j.1572-0241.2008.02086.x-BIB2","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jhep.2006.05.013","article-title":"The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide","volume":"45","author":"Perz","year":"2006","journal-title":"J Hepatol"},{"key":"10.1111\/j.1572-0241.2008.02086.x-BIB3","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/0016-5085(92)91188-A","article-title":"Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver","volume":"103","author":"de Jongh","year":"1992","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1572-0241.2008.02086.x-BIB4","first-page":"77","article-title":"Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis","volume":"21","author":"Fattovich","year":"1995","journal-title":"Hepatology"},{"key":"10.1111\/j.1572-0241.2008.02086.x-BIB5","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/S0168-8278(94)80115-0","article-title":"Survival and prognostic factors in 366 patients with compensated cirrhosis type B: A multicenter study","volume":"21","author":"Realdi","year":"1994","journal-title":"J Hepatol"},{"key":"10.1111\/j.1572-0241.2008.02086.x-BIB6","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa033364","article-title":"Lamivudine for patients with chronic hepatitis B and advanced liver disease","volume":"351","author":"Liaw","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1572-0241.2008.02086.x-BIB7","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.jhep.2006.01.001","article-title":"HBV drug resistance: Mechanisms, detection and interpretation","volume":"44","author":"Shaw","year":"2006","journal-title":"J Hepatol"},{"key":"10.1111\/j.1572-0241.2008.02086.x-BIB8","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.cgh.2006.05.016","article-title":"A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: An update","volume":"4","author":"Keeffe","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1111\/j.1572-0241.2008.02086.x-BIB9","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/j.1478-3231.2005.01134.x","article-title":"Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2005 update","volume":"25","author":"Liaw","year":"2005","journal-title":"Liver Int"},{"key":"10.1111\/j.1572-0241.2008.02086.x-BIB10","volume-title":"Gilead Sciences, Inc","year":"2006","unstructured":"10.\u2002HEPSERA\u00ae (adefovir dipivoxil) package insert. Gilead Sciences, Inc. 2006."},{"key":"10.1111\/j.1572-0241.2008.02086.x-BIB11","unstructured":"11.\u2002 Lai CL , Gane E , Hsu CW , et al. Two-year results from the GLOBE trial in patients with hepatitis B: Greater clinical and antiviral efficacy for telbivudine (LdT) versus lamivudine. Presented at the 57th Annual Meeting of the American Association for the Study of Liver Diseases, October 27-31, 2006."},{"issue":"Suppl 2","key":"10.1111\/j.1572-0241.2008.02086.x-BIB12","article-title":"Entecavir at five years shows long-term maintenance of high genetic barrier to hepatitis B virus resistance","volume":"2","author":"Tenney","year":"2008","journal-title":"Hepatol Int"},{"issue":"Suppl","key":"10.1111\/j.1572-0241.2008.02086.x-BIB13","article-title":"Efficacy and safety of 3 years treatment with entecavir (ETV) in Japanese nucleos(t)ide-naive patients with chronic hepatitis B (CHB)","volume":"2","author":"Takehara","year":"2008","journal-title":"Hepatol Int"},{"key":"10.1111\/j.1572-0241.2008.02086.x-BIB14","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1086\/324003","article-title":"Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection","volume":"184","author":"Colonno","year":"2001","journal-title":"J Infect Dis"},{"key":"10.1111\/j.1572-0241.2008.02086.x-BIB15","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa051285","article-title":"A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B","volume":"354","author":"Chang","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1572-0241.2008.02086.x-BIB16","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa051287","article-title":"Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B","volume":"354","author":"Lai","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1572-0241.2008.02086.x-BIB17","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1053\/j.gastro.2007.08.025","article-title":"Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B","volume":"133","author":"Gish","year":"2007","journal-title":"Gastroenterology"},{"issue":"Suppl 4","key":"10.1111\/j.1572-0241.2008.02086.x-BIB18","first-page":"654A","article-title":"Four-year entecavir treatment in nucleos(t)ide-naive, HBeAg(+) patients: Results from studies ETV-022 and -901","volume":"46","author":"Han","year":"2007","journal-title":"Hepatology"},{"key":"10.1111\/j.1572-0241.2008.02086.x-BIB19","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1053\/j.gastro.2006.04.007","article-title":"Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B","volume":"130","author":"Sherman","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1572-0241.2008.02086.x-BIB20","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/hep.21513","article-title":"Chronic hepatitis B","volume":"45","author":"Lok","year":"2007","journal-title":"Hepatology"},{"key":"10.1111\/j.1572-0241.2008.02086.x-BIB21","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/hep.21723","article-title":"Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis","volume":"46","author":"Buster","year":"2007","journal-title":"Hepatology"}],"container-title":["The American Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00000434-200811000-00016","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T13:45:05Z","timestamp":1786542305000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000434-200811000-00016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11]]},"references-count":21,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2008,11]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1572-0241.2008.02086.x","relation":{},"ISSN":["0002-9270","1572-0241"],"issn-type":[{"value":"0002-9270","type":"print"},{"value":"1572-0241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,11]]}}}